Roche, Biogen handing over $470M in cash to bag two drug programs from Bristol-Myers Squibb
Bristol-Myers Squibb has forged a pair of separate pacts with Roche and Biogen to outlicense two drugs, grabbing a whopping $470 million upfront for the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
